The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: A probabilistic decision model

Value in Health

Volumn 14, Issue 1, 2011, Pages 70-79

  Uthman, Olalekan A ^a   Popoola, Taiwo Aderemi ^b   Yahaya, Ismail ^a   Uthman, Mubashir M B ^c   Aremu, Olatunde ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Center for Evidence Based Global Health Nigeria   (Nigeria)

^c UNIVERSITY OF ILORIN   (Nigeria)

^d UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Cost utility analysis; HIV AIDS; Male circumcision; Probabilistic model; Sub Saharan Africa

Indexed keywords

ADULT MALE CIRCUMCISION; AFRICA; ARTICLE; CIRCUMCISION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; DISABILITY ADJUSTED LIFE YEAR; ECONOMIC EVALUATION; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; ADULT; AFRICA SOUTH OF THE SAHARA; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; META ANALYSIS; MONTE CARLO METHOD; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

ADULT; AFRICA SOUTH OF THE SAHARA; CIRCUMCISION, MALE; COST-BENEFIT ANALYSIS; DECISION TREES; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MODELS, ECONOMETRIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS;

EID: 79952640507     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.011     Document Type: Article

References (51)

1. UNAIDS. Report on the global HIV/AIDS epidemic 2008. Geneva: UNAIDS, 2008.
2. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 2000;14:2361-70.
3. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298.
4. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-56. (Pubitemid 46281312)
5. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657-66.
6. Szabo R, Short RV. How does male circumcision protect against HIV infection? BMJ 2000;320:1592-4. (Pubitemid 30336097)
7. Hussain LA, Lehner T. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995;85:475-84.
8. Cassell MM, Halperin DT, Shelton JD, et al. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006;332:605-7. (Pubitemid 44365764)
9. Jones R, Gazzard B, Halima Y. Preventing HIV infection. BMJ 2005;331:1285-6. (Pubitemid 41746456)
10. Pinkerton SD, Holtgrave DR, DiFranceisco WJ, et al. Costeffectiveness of a community-level HIV risk reduction intervention. Am J Public Health 1998;88:1239-42. (Pubitemid 28361372)
11. Auvert B, Marseille E, Korenromp EL, et al. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in sub-Saharan Africa. PLoS One 2008;3:e2679.
12. Bollinger LA, Stover J, Musuka G, et al. The cost and impact of male circumcision on HIV/AIDS in Botswana. J Int AIDS Soc 2009;12:7.
13. Fieno JV. Costing adult male circumcision in high HIV prevalence, low circumcision rate countries. Aids Care 2008;20:515-20.
14. Gray RH, Li X, Kigozi G, et al. The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 2007;21:845-50. (Pubitemid 46573156)
15. Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Medicine 2006;3:2349-58. (Pubitemid 46026452)
16. Uthman OA, Popoola TA, Uthman MM, et al. Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a systematic review. PLoS One 2010;5:e9628.
17. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339-47. (Pubitemid 40514748)
18. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87. (Pubitemid 34041389)
19. Fenwick E, Marshall DA, Levy AR, et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006;6:52.
20. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2009.
21. Meaure D H S. Demographic and Health Surveys. Calverton: ICF Macro, 2009.
22. Bailey RC, Egesah O, Rosenberg S. Male circumcision for HIV prevention: a prospective study of complications in clinical and traditional settings in Bungoma, Kenya. Bull World Health Organ 2008;86:669-77.
23. Kiwanuka N, Gray R, Serwadda D, et al. Circumcision for HIV of a pilot study in Rakai, Uganda., XV International AIDS Conference, 2004.
24. Krieger JN, Bailey RC, Opeya J, et al. Adult male circumcision: results of a standardized procedure in Kisumu District, Kenya. BJU Int 2005;96:1109-13. (Pubitemid 41531424)
25. Lagarde E, Taljaard D, Puren A, et al. High rate of adverse events following circumcision of young male adults with the Tara KLamp technique: a randomised trial in South Africa. S Afr Med J 2009;99:163-9.
26. Magoha GA. Circumcision in various Nigerian and Kenyan hospitals. East Afr Med J 1999;76:583-6.
27. Shittu OB, Shokunbi WA. Circumcision in hemophiliacs: the Nigerian experience. Hemophilia 2001;7:534-6.
28. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Appl Probab 1950;21:607-11.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
30. Siegfried N, Muller M, Deeks JJ, et al. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2009: CD003362.
31. Bachmann MO. Cost effectiveness of community-based therapeutic care for children with severe acute malnutrition in Zambia: decision tree model. Cost Eff Resour Alloc 2009;7:2.
32. WHO. Ad Hoc Committee on Health Research Relating to Future Intervention Options. Investing in Health Research and Development. Geneva: World Health Organization, 1996.
33. Ehlers L, Overvad K, Sorensen J, et al. Analysis of cost effectiveness of screening Danish men aged 65 for abdominal aortic aneurysm. BMJ 2009;338:b2243.
34. Hutubessy R, Chisholm D, Edejer TT. Generalized costeffectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 2003;1:8.
35. Baltussen RM, Hutubessy RC, Evans DB, et al. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Health Care 2002;18:112-9. (Pubitemid 34408533)
36. Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:669-77.
37. Agot KE, Kiarie JN, Nguyen HQ, et al. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007;44:66-70. (Pubitemid 46052222)
38. Mattson CL, Campbell RT, Bailey RC, et al. Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. Plos One 2008;3:e2443.
39. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Eff Resour Alloc 2006;4:20.
40. Galárraga O, Colchero MA, Wamai RG, et al. HIV prevention cost-effectiveness: a systematic review. BMC Public Health 2009;9(Suppl. 1):s5.
41. Creese A, Floyd K, Alban A, et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002;359:1635-43.
42. Hogan DR, Baltussen R, Hayashi C, et al. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 2005;331:1431-7.
43. Skordis J, Nattrass N. Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa. J Health Econ 2002;21:405-21. (Pubitemid 34275440)
44. Soderlund N, Zwi K, Kinghorn A, et al. Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. BMJ 1999;318:1650-6. (Pubitemid 29276758)
45. Wilkinson D, Floyd K, Gilks CF. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity. AIDS 1998;12:1675-82. (Pubitemid 28418339)
46. Wilkinson D, Floyd K, Gilks CF. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa. S Afr Med J 2000;90:794-8.
47. Boulle A, Kenyon C, Skordis J, et al. Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa. S Afr Med J 2002;92:811-7. (Pubitemid 35238291)
48. Kenyon C, Skordis J, Boulle A, et al. The ART of rationing-the need for a new approach to rationing health interventions. S Afr Med J 2003;93:56-60. (Pubitemid 36131778)
49. Marseille E, Kahn JG, Billinghurst K, et al. Cost-effectiveness of the female condom in preventing HIV and STDs in commercial sex workers in rural South Africa. Soc Sci Med 2001;52:135-48.
50. Soorapanth S, Sansom S, Bulterys M, et al. Costeffectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings. J Acquir Immune Defic Syndr 2006;42:213-21. (Pubitemid 43884717)
51. Templeton DJ, Millett GA, Grulich AE. Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men. Curr Opin Infect Dis 2010;23:45-52.